Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Melissa Strafford, et al v. Eli Lilly and Company
Case Number:
15-56808
Court:
Nature of Suit:
Companies
Sectors & Industries:
-
October 12, 2017
Microsoft Ruling Dooms Cymbalta Labeling Suit: 9th Circ.
The Ninth Circuit on Thursday dismissed three consumers' bid for class certification in litigation accusing Eli Lilly & Co. of hiding the magnitude of withdrawal risks for its antidepressant Cymbalta, finding that the U.S. Supreme Court's recent decision in Microsoft Corp. v. Baker doomed the appeal.
-
June 13, 2017
Microsoft Ruling Backs Cymbalta Suit, Lilly Tells 9th Circ.
The U.S. Supreme Court's Monday decision in Microsoft Corp. v. Baker that plaintiffs can't voluntarily dismiss their suit just to appeal a denial of class certification supports Eli Lilly & Co. in similar litigation over whether the drugmaker hid the magnitude of withdrawal risks for its antidepressant Cymbalta, Lilly told the Ninth Circuit on Tuesday.
-
February 06, 2017
Stay Cymbalta Suit Until Xbox Ruling, Lilly Tells 9th Circ.
Eli Lilly and Co. on Friday asked the Ninth Circuit to hold off on oral arguments over whether to grant class certification to consumers accusing the drugmaker of hiding withdrawal risks related to the antidepressant Cymbalta until the U.S. Supreme Court makes a decision in a Microsoft case regarding jurisdiction.
-
August 23, 2016
Eli Lilly Urges 9th Circ. Not To Revive Cymbalta Suit
Eli Lilly and Co. on Monday urged the Ninth Circuit to affirm the denial of class certification and an injunction sought by three consumers accusing the pharmaceutical giant of failing to warn them of antidepressant Cymbalta's withdrawal risk.
-
June 03, 2016
Cymbalta Users Urge Revival Of Drug's Withdrawal Claims
Three consumers accusing Eli Lilly & Co. of failing to warn them of the withdrawal risks of its antidepressant Cymbalta told the Ninth Circuit that a lower court erred in ruling that they can't pursue an injunction or statewide classes, before they could even conduct a full discovery.